PsiOxus Therapeutics Appoints Howard Davis, Ph.D. as Chief Executive Officer

Howard Davis, Ph.D.

OXFORD, England– PsiOxus Therapeutics, Ltd. (PsiOxus), a clinical-stage biotechnology company developing a novel platform technology for the targeted delivery of therapeutic transgenes to solid tumors, today announces the appointment of Howard Davis, Ph.D., as Chief Executive Officer. Dr. Davis will be based in the greater Boston metropolitan area where he will establish the company’s U.S. operations. He succeeds interim CEO Priya Mande who will continue to serve the company in the new role of Chief Operating Officer and U.K. President.

“Howard joins us at a critical stage for PsiOxus, as we rapidly progress our NG-350A and NG-641 immuno-oncology programs through early clinical studies and leverage our novel T-SIGn® platform to further expand our pipeline,” said Duncan Higgons, Chairman of the Board of PsiOxus. “We believe Howard’s exceptional leadership skills combined with his extensive experience across all phases of the product development lifecycle will help PsiOxus realize the full promise of its platform.”

“PsiOxus has developed a groundbreaking platform in the T-SIGn® viral vector system and the company’s pipeline has the potential to truly revolutionize the treatment of solid tumors,” said Dr. Davis. “With the team’s rapid advancement of the NG-350A and NG-641 programs into the clinic, we anticipate a significant flow of clinical data in the coming quarters. I am thrilled to join the PsiOxus team at this exciting juncture and look forward to leading the company into its next chapter as we seek to deliver on our mission to positively impact the lives of people living with cancer.”

Dr. Davis brings more than 20 years of experience to PsiOxus having served in diverse roles across VC-backed biotech and large pharma companies spanning a broad range of therapeutic areas including neuroscience, ophthalmology, immunology, and rare diseases. Most recently, Dr. Davis worked with Atlas Venture on the launch of Third Harmonic Bio, a clinical stage immunology company where he served as COO with responsibility for business development, new product planning, finance, HR, legal / IP, and IT. During his tenure, he spearheaded fundraising efforts that secured $155 million in private financing to support the company’s advancement of its lead clinical stage molecule. Earlier in his career, Dr. Davis served as a Principal at Flagship Pioneering where he focused on expanding the firm’s portfolio of corporate strategic partnerships while also supporting new company creation efforts. Prior to Flagship, Dr. Davis held roles of increasing responsibility at Biogen and Novartis across a range of functional areas including commercial, manufacturing, pipeline program leadership and corporate strategy. He began his industry career at Boston Consulting Group where he advised both large pharma and biotech clients. Dr. Davis holds a Bachelor of Science degree in Chemical Engineering from Yale University and a Ph.D. in biomedical engineering from the Harvard University / Massachusetts Institute of Technology Division of Health Sciences & Technology.

“Howard is uniquely positioned to lead PsiOxus through its next phase of growth as we establish our U.S. presence to support preparations for late-stage clinical development, expanded partnerships, and U.S.-focused financing activities. I would like to thank Priya Mande for her leadership of the company during the CEO search process, and we look forward to her continued valuable contributions as COO and U.K. President,” said Mr. Higgons. (IANS)